Patients receiving onabotulinumtoxinA demonstrated significantly improved quality of life scores at 180 and 270 days after treatment ( p = 0.02 and 0.03 , respectively ) as well as significantly lower International Consultation on Incontinence Questionnaire ( ICIQ ) scores ( p < 0.05 ) .